Kabizolid

Added advantage against tough infection

  • Linezolid is a synthetic antibiotic of oxazolidine class and active against most Gram-positive bacteria.
  • It acts a protein synthesis inhibitor stopping the growth of bacteria by disrupting their production of proteins (bacteriostatic action).
  • The exact mechanism of action of linezolid appears to be unique in that it blocks the initiation of protein production, and not one of the later steps.

KABIZOLID l.V. lniection is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms:

  • Vancomycin-resistant Enterococcus faecium infections, including cases with concurrent bacteremia.
  • Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and resistant strains), 'or Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP]).
  • Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by Staphylococcus aureus (methicillinsusceptibleand-resistant strains), Streptococcus pyrogenes, or Streptococcus agatactiae.
  • Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible only) or Streptococcus pyogenes.
  • Community-acquired pneumonia caused by Streptocaccus pneumoniae (including multidrug resistant strains [MDRSP]), including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible strains only).

Packaging: KABIZOLID I.V. Injection Freeflex bag of 100 ml and 300 ml

 Dosage and Route of Administration  
INDICATIONPEDIATRIC PATIENTS (BIRTH THROUGH 11 YEARS OF AGE)ADULTS AND ADOLESCENTS (12 YEARS AND OLDER)RECOMMENDED DURATION OF TREATMENT (CONSECUTIVE DAYS)
Nosocomial pneumonia10 mg/kg iv or oral every 8 hours600 mg iv or oral every 12 hours10 to 14
Community-acquired pneumonia, including concurrent bacteremia

10 mg/kg iv or oral every 8 hours

600 mg iv or oral every 12 hours10 to 14
Complicated skin and skin structure infections10 mg/kg iv or oral every 8 hours600 mg iv or oral every 12 hours10 to 14
Vancomycin-resistant Enterococcus faecium infections, including concurrent bacteremia10 mg/kg iv or oral every 8 hours600 mg iv or oral every 12 hours14 to 28
Uncomplicated skin and skin structure infectionsLess than 5 years: 10 mg/kg iv or oral every 8 hours, 5 - 11 years: 10 mg/kg iv or oral every 12 hoursAdults: 400 mg every 12 hours, Adolescents: 600 mg oral every 12 hours10 to 14



 

 

  • Linezolid solution for injection 2mg/ml

Each 100 ml contains

Linezolid IP                       0.2 g

Dextrose (Anhydrous) IP   5.0 g

Water for Injections IP      q.s.